Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| peripheral blood | 15 studies | 32% ± 13% | |
| lung | 9 studies | 31% ± 12% | |
| lymph node | 5 studies | 43% ± 22% | |
| intestine | 4 studies | 23% ± 8% | |
| brain | 3 studies | 41% ± 20% | |
| kidney | 3 studies | 43% ± 15% | |
| bone marrow | 3 studies | 30% ± 10% | |
| uterus | 3 studies | 23% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| kidney | 98% | 3190.15 | 87 / 89 | 85% | 528.20 | 767 / 901 |
| lung | 99% | 10849.49 | 573 / 578 | 83% | 573.26 | 953 / 1155 |
| breast | 97% | 4495.28 | 447 / 459 | 84% | 376.29 | 937 / 1118 |
| thymus | 85% | 2717.45 | 553 / 653 | 79% | 397.35 | 480 / 605 |
| uterus | 82% | 2214.50 | 139 / 170 | 71% | 401.35 | 328 / 459 |
| bladder | 81% | 2163.19 | 17 / 21 | 61% | 299.47 | 305 / 504 |
| intestine | 79% | 2343.19 | 766 / 966 | 58% | 237.70 | 304 / 527 |
| skin | 59% | 1311.22 | 1076 / 1809 | 75% | 454.20 | 356 / 472 |
| prostate | 71% | 1833.49 | 173 / 245 | 61% | 135.75 | 305 / 502 |
| adrenal gland | 79% | 3311.10 | 203 / 258 | 44% | 157.88 | 101 / 230 |
| stomach | 56% | 1150.78 | 200 / 359 | 60% | 219.00 | 171 / 286 |
| esophagus | 68% | 1358.18 | 986 / 1445 | 39% | 99.90 | 71 / 183 |
| pancreas | 21% | 293.07 | 69 / 328 | 81% | 397.32 | 145 / 178 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 1694.05 | 29 / 29 |
| spleen | 99% | 9808.81 | 239 / 241 | 0% | 0 | 0 / 0 |
| adipose | 98% | 5251.00 | 1174 / 1204 | 0% | 0 | 0 / 0 |
| ovary | 40% | 784.62 | 72 / 180 | 56% | 252.51 | 242 / 430 |
| peripheral blood | 90% | 6594.12 | 833 / 929 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 89% | 396.86 | 40 / 45 |
| liver | 31% | 559.58 | 69 / 226 | 51% | 155.73 | 206 / 406 |
| blood vessel | 81% | 2429.51 | 1079 / 1335 | 0% | 0 | 0 / 0 |
| brain | 23% | 389.70 | 599 / 2642 | 48% | 169.26 | 336 / 705 |
| heart | 62% | 1323.41 | 535 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 35% | 139.32 | 28 / 80 |
| muscle | 33% | 468.49 | 261 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0050870 | Biological process | positive regulation of T cell activation |
| GO_0002503 | Biological process | peptide antigen assembly with MHC class II protein complex |
| GO_0002250 | Biological process | adaptive immune response |
| GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
| GO_0050778 | Biological process | positive regulation of immune response |
| GO_0031902 | Cellular component | late endosome membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0030666 | Cellular component | endocytic vesicle membrane |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0030669 | Cellular component | clathrin-coated endocytic vesicle membrane |
| GO_0032588 | Cellular component | trans-Golgi network membrane |
| GO_0000139 | Cellular component | Golgi membrane |
| GO_0098553 | Cellular component | lumenal side of endoplasmic reticulum membrane |
| GO_0042613 | Cellular component | MHC class II protein complex |
| GO_0012507 | Cellular component | ER to Golgi transport vesicle membrane |
| GO_0030658 | Cellular component | transport vesicle membrane |
| GO_0005765 | Cellular component | lysosomal membrane |
| GO_0023026 | Molecular function | MHC class II protein complex binding |
| GO_0042605 | Molecular function | peptide antigen binding |
| Gene name | HLA-DRB5 |
| Protein name | MHC class II antigen MHC Class II antigen MHC class I antigen HLA class II histocompatibility antigen HLA-DRB5 protein HLA class II histocompatibility antigen, DR beta 5 chain (DR beta-5) (DR2-beta-2) (Dw2) (MHC class II antigen DRB5) MHC class II DRB5 |
| Synonyms | |
| Description | FUNCTION: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. |
| Accessions | A0A678ZYV2 A0A455JW93 A0A5A4LIN2 E9NVG9 A0A678ZWE2 A0A3S6RGV0 A0A6B7HG77 A0A1C8DWJ8 A0A6B7KQG9 A0A3S6RGW9 A0A5H2UZL2 A0A1X9I5C0 A0A455JW64 A0A678ZHU5 A0A7L4X6M0 A0A180H5X1 A0A3S6RJ68 A0A5H2UTJ4 A0A1X9I6P7 A0A858B8J6 A0A5H2UD16 A0A5C1IZ51 A0A4D6PFE0 A0A2I4Q009 A0A5A4LMJ1 A0A5H2UTK3 A0A286MCI9 A0A173ADY0 A0A4Y5R8N3 O78167 A0A1X9I652 A0A7L4X6Z3 A0A1X9I5D9 A0A3S6RGZ3 A0A024F8S6 A0A0P1GL35 A0A173ADR6 A0A678ZWD7 A0A3S6RGY6 A1A426 A0A5A4LHH9 A0A4P2STN0 A0A6B7HFE3 A0A3S6RGW1 A0A678ZL86 A0A5H2USU8 A0A173ADS0 A0A286MCJ0 A0A678ZHV8 A0A455JW87 A0A3S6RGW6 A0A2D1CBP1 A0A1X9I5B4 A0A8E4J7T4 A0A3S6RH00 A0A455JU83 A0A173ADR7 A0A1X9I6N1 A0A6B7HFN0 A0A2H4FZY7 A0A3S6RGY0 A0A6B7HHG5 A0A678ZHS4 A0A173ADS8 ENST00000374975.4 A0A3S6RIV9 A0A2H4V0U7 A0A2U7NH26 A1A428 A0A0Y0BU96 A0A2H4FZZ2 A0A455JWD9 A0A8F7CEZ1 A0A6B7HG09 A0A5H2UGE5 A1A424 A0A3S6RGY4 Q06663 A0A6B7HG19 A0A6B7G0G1 A0A5H2UGD6 A0A3S6RGX7 A0A2U7NEG4 A0A858B8K1 A1A425 A0A3S6RGX5 A0A5A4LJ87 A0A3S6RJ76 A0A288QAF4 A0A173ADW6 A0A2U7NN64 A0A5A4LM62 A0A5A4LU61 A0A678ZW25 A0A1X9I580 A0A5H2UWT8 A0A858LGW3 A0A455JW59 A0A3S6RGZ8 Q06664 A0A858B8L5 A0A5B9R3U1 A0A2H4V0T3 A0A6B7G365 A0A6B7HHE4 A0A288Q9N4 A0A5A4LHR5 A0A3S6RIX4 A0A2H4G2W3 A0A3S6RGX0 A0A180H5S5 A0A5H2UXD3 A0A024F9V3 A0A493QPA3 A0A6B7HG90 A0A4P2SUA6 A0A4P2SSI6 A0A2H4G000 A0A5A4LIP2 Q5EEQ8 A0A678ZLC2 A0A5A4M3G6 A0A678ZG60 A0A5A4LJ78 A0A7T5V901 A0A5A4LHS2 A0A3S6RIV4 A0A3S6RGY9 A0A4V0NPB7 A0A455JUL2 A0A2U7MWQ3 A0A6B7IBC0 A0A4P2ST83 A0A2H4G4H7 A0A678ZVG0 A0A8F9WB44 A0A1X9I554 A0A1X9I615 A0A678ZGB0 A0A3S6RGX3 A0A3S6RJ81 A0A1X9I553 A0A1X9I574 A0A2U7N6X0 A0A180H6P7 A0A4P2SS76 A0A1X9I575 A0A1L2BMT9 A0A3S6RGY2 A0A5H2UGC8 A0A2H4G4F0 A0A7L7TMK3 A0A1S5QRQ4 A0A5H2UD01 A0A1X9I564 A0A5H2URL3 A0A3S6RGV6 Q2YHL2 A0A3S6RGW4 A0A1X9I631 A0A3S6RIW4 A0A455JSN5 A0A455JX72 A0A493QPA5 A0A286MCI8 Q8HWH1 A0A678ZG49 A0A5H2UFR4 A0A3S6RGV9 A0A2H4FZY0 A0A678ZW40 A0A5H2UZL8 A0A8E4J5P0 I2G868 A0A1X9I577 A0A173ADS1 A0A5A4LKQ5 A0A1B0Z6G7 A0A858LHB0 A0A5H2UWV0 A0A068B7P5 A0A2I4Q025 A0A346XQV5 A0A8F4G8Y8 A0A3S6RGV4 A0A3S6RGY7 A0A5H2UDJ9 A0A5Q0TWI6 A0A2U7NH21 Q5W1E2 A0A288QSA1 A0A678ZKA9 Q06654 A0A180H6K7 A0A2U7MWQ4 A0A4P2SSE5 A0A858LGC5 A0A6B7HG21 A0A6B7G0H4 A0A180H767 A0A2Z4LKS3 A0A7L4X6L8 A0A3S6RGW5 Q30154 A0A1X9I6P2 A0A180H5R4 A0A678ZW31 A0A678ZKC9 A0A024F8R0 A0A4P2SSW0 A0A678ZVF7 Q5TJ21 A0A5H2UTI7 A0A2H4V0T6 A0A1X9I5D5 A0A678ZYX3 A0A3S6RJ90 A0A2H4G0J5 A0A2U7N3K4 A0A4P2SS72 A0A1S5QRQ1 A0A3S6RGX4 A0A678ZYU3 A0A180H5P8 A1A427 A0A1X9I5E6 A0A1X9I5D1 A0A5A4LMM3 A0A5H2UFS2 A0A1L2BMT6 O46698 A0A678ZWC8 A0A678ZG79 A0A1X9I586 A0A173ADR4 A0A5H2UZK5 A0A3S6RGV7 A0A678ZGG9 A0A3S6RIW8 A0A5H2UFT4 A0A8A3WS00 A0A286MCI7 A0A3S6RGX9 A0A5H2UXB8 A0A5H2UDS1 A0A6B7HG64 A0A1X9I5Q0 A0A4P2SUU4 A0A1L2BMV3 A0A5A4LM46 A0A858LFY4 A0A5H2URK8 A0A678ZVG4 A0A3S6RJA0 A0A678ZKB9 A0A858LNC4 A0A2U7N9V7 Q9TPE2 A0A678ZG81 A0A678ZGG0 A0A455JWD3 A0A493QPA4 A0A455JUK7 A0A2U7NIE0 A0A5H2UST8 A0A5A4LJN3 Q3LTJ2 A0A3S6RGW8 A0A678ZGA1 A0A2U7MZV1 A0A3S6RGW3 A0A1S5QRQ2 A0A455JVZ5 A0A5H2UD10 A0A4D6DKR6 A0A678ZG91 A0A3S6RGZ1 A0A455JU77 A0A678ZK98 A0A455JSP5 A0A678ZW46 A0A3S6RGV1 A0A5A4M3H1 A0A5H2UDR3 A0A678ZGH9 A0A5H2UXC4 A0A678ZLG2 A0A678ZW51 A0A1X9I562 A0A4Y5RB73 A0A173ADR5 A0A678ZG69 A0A678ZHT4 A0A678ZWE7 A0A858B7N5 A0A678ZGF1 A0A6B7IAJ8 A0A346MPT5 A0A1L2BMT2 A0A3S6RGY1 A0A6B7G272 A0A6B7L1A2 A0A5H2UST2 A0A678ZVF4 A0A3S6RJ83 A0A2H4FZZ0 A0A1X9I571 Q30151 A0A7S5L7K5 A0A1X9I5N7 A0A3S6RGX1 A0A678ZYZ0 A0A5H2UWU3 A0A678ZYW4 A0A858LF51 A0A858LHE6 A0A3S6RJ87 A0A2H4FZZ8 A0A1S5QRP1 A0A678ZL59 A0A1X9I565 A0A3S6RGX2 A0A7L4X6T4 A0A5A4LU70 A0A3S6RJ95 A0A1L2BMU9 A0A6B7G1F0 A0A5H2URL8 A0A1X9I596 A0A455JX70 |
